Core Viewpoint - Haemonetics reported quarterly earnings of $1.1 per share, exceeding the Zacks Consensus Estimate of $1.01 per share, and showing a slight increase from $1.02 per share a year ago [1][2]. Financial Performance - The earnings surprise for the quarter was +8.91%, with the company also surpassing earnings expectations in the previous quarter by +1.64% [2]. - Revenues for the quarter ended June 2025 were $321.39 million, which was 5.97% above the Zacks Consensus Estimate, although it represented a decline from $336.17 million in the same quarter last year [3]. Stock Performance - Haemonetics shares have declined approximately 3% since the beginning of the year, contrasting with a 7.9% gain in the S&P 500 [4]. - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [7]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.16, with projected revenues of $321.11 million, and for the current fiscal year, the EPS estimate is $4.89 on revenues of $1.3 billion [8]. - The outlook for the Medical - Products industry, where Haemonetics operates, is currently in the bottom 37% of Zacks industries, which may impact stock performance [9].

Core Viewpoint - Phibro Animal Health (PAHC) reported quarterly earnings of $0.63 per share, exceeding the Zacks Consensus Estimate of $0.52 per share, and showing significant growth from $0.31 per share a year ago [1][2]. Financial Performance - The earnings surprise for the quarter was 21.15%, with the company previously expected to earn $0.42 per share but actually earning $0.54, resulting in a surprise of 28.57% [2]. - Phibro's revenues for the quarter were $347.8 million, slightly missing the Zacks Consensus Estimate by 0.78%, compared to $263.2 million in the same quarter last year [3]. - Over the last four quarters, the company has surpassed consensus EPS estimates four times and topped revenue estimates twice [2][3]. Stock Performance - Phibro shares have declined approximately 9.3% since the beginning of the year, while the S&P 500 has decreased by 4.7% [4]. - The current Zacks Rank for Phibro is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.53, with expected revenues of $355.98 million, and for the current fiscal year, the estimate is $1.94 on $1.28 billion in revenues [8]. - The outlook for the Medical - Products industry, to which Phibro belongs, is currently in the bottom 28% of over 250 Zacks industries, which may impact stock performance [9].